• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/16/25 5:00:10 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    8-K 1 mnmd-20250616.htm 8-K 8-K

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 12, 2025

     

     

    Mind Medicine (MindMed) Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    British Columbia

    001-40360

    98-1582438

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    One World Trade Center

    Suite 8500

     

    New York, New York

     

    10007

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (212) 220-6633

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Shares

     

    MNMD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Approval of Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan

    As described in Item 5.07 below, on June 12, 2025, Mind Medicine (MindMed) Inc. (the “Company”) held its 2025 Annual General and Special Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders approved the adoption of the Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan (the “2025 Equity Incentive Plan”). The 2025 Equity Incentive Plan replaces the Mind Medicine (MindMed) Inc. Stock Option Plan and the Mind Medicine (MindMed) Inc. Performance and Restricted Share Unit Plan, which were both retired on March 14, 2025. The 2025 Equity Incentive Plan was previously approved, subject to shareholder approval, by the Company’s Board of Directors (the “Board”) on April 22, 2025.

     

    The 2025 Equity Incentive Plan authorizes for issuance an aggregate of 4,500,000 common shares, no par value per share, of the Company (“Common Shares”). Additional information regarding the 2025 Equity Incentive Plan, including a summary of the material terms of the 2025 Equity Incentive Plan, is set forth in the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company with the Securities and Exchange Commission on April 23, 2025, which information is incorporated herein by reference. Such information and the foregoing description of the 2025 Equity Incentive Plan do not purport to be complete and are qualified in their entirety by reference to the full text of the Company’s 2025 Equity Incentive Plan, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On June 12, 2025, the Company held its Annual Meeting. As of April 16, 2025, the record date for the Annual Meeting, 75,551,538 Common Shares were outstanding and entitled to vote at the Annual Meeting. A quorum was present at the Annual Meeting under the Company’s amended and restated articles, and there were 42,850,491 Common Shares present or represented at the Annual Meeting by valid proxies representing approximately 56.7% of the Common Shares entitled to vote at the Annual Meeting. The Company’s shareholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s Proxy Statement.

    Set forth below are the final voting results for the Annual Meeting as certified by the Independent Scrutineer of Elections on June 12, 2025, as well as a description of the proposals voted on at the Annual Meeting.

    Proposal 1 – Election of Directors

    The Company’s six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Board until the 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) and until his or her successor is duly elected or qualified, by the following votes:

     

    Company Board Nominee

    Votes For

    Votes
    Withheld

    Broker Non-Votes

    Robert Barrow

     29,014,352

    130,402

    13,705,737

    Dr. Suzanne Bruhn

     28,873,110

    271,644

    13,705,737

    Dr. Roger Crystal

    27,862,876

    1,281,878

    13,705,737

    David Gryska

     28,987,808

    156,946

    13,705,737

    Andreas Krebs

    28,906,903

    237,851

    13,705,737

    Carol A. Vallone

    28,914,450

    230,304

    13,705,737

    Proposal 2 – Appointment of Auditor

    The shareholders approved the appointment of KPMG LLP as the independent registered public accounting firm (auditor) of the Company until the 2026 Annual Meeting by the following votes:

    Votes For

    Votes Withheld

    Broker Non-Votes

     42,583,160

    267,331

    0

    Proposal 3 – Approval of 2025 Equity Incentive Plans

    The shareholders approved the 2025 Equity Incentive Plan by the following votes:


     

    Votes For

    Votes Against

    Votes Abstain

    Broker Non-Votes

    28,452,155

    581,911

    110,688

    13,705,737

     

     

    Item 9.01 Financial Statements and Exhibits.

    Exhibit No.

    Description

    10.1

    Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    MIND MEDICINE (MINDMED) INC.

     

     

     

     

    Date:

    June 16, 2025

    By:

    /s/ Robert Barrow

     

     

     

    Chief Executive Officer

     


    Get the next $MNMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/20/24 9:14:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed Announces New Employee Inducement Grants

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the last trading day on which MindMed's common shares traded prior to the date of the respective

      6/9/25 4:01:00 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Participate in June Investor Conferences

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Presentation Date and Time: Thursday, June 5, 2025 at 12:50 PM ET Location: New York, NY Webcast Link: Jefferies Global Healthcare Conference H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Format: Pre-recorded Fireside Chat Date and Time: Tuesday, June 17, 2025 at 7:00 AM ET Location: Virtual We

      5/28/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

      5/27/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Sullivan Mark sold $78,139 worth of shares (11,491 units at $6.80), decreasing direct ownership by 4% to 305,130 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/26/25 4:30:09 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert sold $180,139 worth of shares (26,491 units at $6.80), decreasing direct ownership by 3% to 830,065 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/26/25 4:30:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Medical Officer Karlin Daniel sold $53,366 worth of shares (7,848 units at $6.80), decreasing direct ownership by 2% to 438,329 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/26/25 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form 144 filed by Mind Medicine (MindMed) Inc.

      144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      6/25/25 4:07:28 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 filed by Mind Medicine (MindMed) Inc.

      S-8 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/20/25 4:05:51 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/16/25 5:00:10 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on MindMed with a new price target

      Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

      1/28/25 7:14:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on MindMed with a new price target

      Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

      12/20/24 7:44:37 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Leerink Partners resumed coverage on MindMed with a new price target

      Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

      10/14/24 7:36:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Financials

    Live finance-specific insights

    See more
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

      --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

      3/6/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

      5/27/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Matt Wiley as Chief Commercial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

      3/17/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

      12/3/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

      SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      11/14/24 4:05:16 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/21/24 4:05:38 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/15/24 4:08:37 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care